MedTrace Logo

Role of Genomic Imprinting in Cancer Diagnosis

NCT03882684 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 1500

Last updated 2019-03-20

No results posted yet for this study

Summary

The current research focus for cancer diagonosis is classical genetics, named "driving genes". However, not all cancer patients have typical genetic alterations, especially at early stage. In the past dacades, accumulating evidences have revealed that more than 80% diseases are closely related to epigenetic changes. The normally silenced copy of imprinted genes are reactivated at early stage of cancers, and finally proceed to copy number variation. This study will screen for a panel of imprinted genes and build quantitative models to assist the diagnosis of multiple cancers.

Conditions

  • Early Diagnosis
  • Cancer
  • Biomarker
  • Genomic Imprinting

Interventions

DIAGNOSTIC_TEST

In-situ imprinting detection

The loss of imprinting (LOI) and copy number variation (CNV) from biopsies will be tested by LiSen in-situ imprinting detection.

Sponsors & Collaborators

  • LiSen Imprinting Diagnostic Inc.

    collaborator UNKNOWN

  • Chinese Alliance Against Lung Cancer

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-07-01
Primary Completion
2019-03-31
Completion
2020-06-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03882684 on ClinicalTrials.gov